Abstract: . . .  beta-thalassaemia major. Eur Heart J 2002; 23:147-56. 27. Derchi G, Fonti A, Forni GL, et al. Pul- monary hypertension in patients with thal- assemia major. Am Heart J 1999;138:384. 28. Grisaru D, Rachmilewitz EA, Mosseri M, et al. Cardiopulmonary assessment in beta-thalassemia major. Chest 1990;98: 1138-42. 29. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-9. 30. Morris CR, . . .
. . .  risk factor for vaso-occlusive complications in sickle cell disease? Am J Med Sci 1993;305:150-6. 39. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sick- le cell anemia. Am J Med 1997;102:171-7. 40. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94. 41. Platt OS, Brambilla DJ, Rosse . . .
. . .  Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94. 41. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectan- cy and risk factors for early death. N Engl J Med 1994;330:1639-44. 42. Atweh GF, Schechter AN. Pharmacolog- ic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 2001;8:123-30. 43. Noguchi CT, Rodgers . . .
. . .  Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94. 41. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectan- cy and risk factors for early death. N Engl J Med 1994;330:1639-44. 42. Atweh GF, Schechter AN. Pharmacolog- ic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 2001;8:123-30. 43. Noguchi CT, Rodgers GP, . . .
. . .  Atweh GF, Schechter AN. Pharmacolog- ic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 2001;8:123-30. 43. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell dis- ease. N Engl J Med 1988;318:96-9. Copyright 2004 Massachusetts Medical Society. Downloaded from www.nejm.org at HHS LIBRARIES CONSORTIUM on February 26, 2004. Copyright 2004 Massachusetts Medical Society. All rights reserved.  . . .
--3000,5,300,3357,55955